Education
About Us
Working with TipRanks
Follow Us
Nicox SA (FR:ALCOX)
:ALCOX
ALCOX Stock Chart & Stats
€0.43
>-€0.01(-1.83%)
At close: 4:00 PM EST
€0.43
>-€0.01(-1.83%)
Day’s Range― - ―
52-Week Range€0.20 - €0.65
Previous CloseN/A
Volume114.32K
Average Volume (3M)588.51K
Market Cap
€38.34M
Enterprise Value€37.89M
Total Cash (Recent Filing)€11.26M
Total Debt (Recent Filing)€25.79M
Price to Earnings (P/E)―
Beta1.49
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding88,441,770
10 Day Avg. Volume452,436
30 Day Avg. Volume588,508
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)4.11
Price to Sales (P/S)1.78
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€1.50Price Target Upside248.84% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyNCX 470 met the primary efficacy endpoint in a second Phase 3 glaucoma trial and demonstrated faster onset and stronger intraocular pressure reduction than standard therapy, which should support favorable labeling and physician adoption if approved.
Partnership And MilestonesPartner Kowa is financing late-stage development, leading regulatory efforts and has triggered milestone payments while preserving eligibility for further milestones and royalties, reducing Nicox's funding burden and signaling strong commercial commitment.
Regulatory ProgressU.S. regulator provided positive written feedback on the planned NDA for NCX 470, noting the data package and submission format are generally acceptable and requesting only limited pharmacokinetic data, supporting a timely FDA filing.
Bears Say
Commercial Competition RiskAnalyst notes that limited commercial uptake due to intense market competition or challenges in market penetration could restrict sales despite positive clinical data.
Regulatory Approval RiskAnalyst highlights the risk that failure to obtain regulatory approval for NCX 470 would prevent market entry and materially impair revenue prospects.
Shareholder Dilution RiskAnalyst warns that the company may need to raise additional capital, which could dilute existing shareholders and weigh on the stock.
Nicox SA News
ALCOX FAQ
What was Nicox SA’s price range in the past 12 months?
Nicox SA lowest stock price was €0.20 and its highest was €0.65 in the past 12 months.
What is Nicox SA’s market cap?
Nicox SA’s market cap is €38.34M.
When is Nicox SA’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Nicox SA’s earnings last quarter?
Currently, no data Available
Is Nicox SA overvalued?
According to Wall Street analysts Nicox SA’s price is currently Undervalued.
Does Nicox SA pay dividends?
Nicox SA does not currently pay dividends.
What is Nicox SA’s EPS estimate?
Nicox SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nicox SA have?
Nicox SA has 88,441,770 shares outstanding.
What happened to Nicox SA’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Nicox SA?
Currently, no hedge funds are holding shares in FR:ALCOX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nicox SA
Nicox S.A. operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. Its lead product candidate is NCX 470, a novel nitric oxide-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial. The company is also developing NCX 4251, a novel patented ophthalmic suspension of fluticasone propionate nanocrystals that is in Phase 2b clinical trial for the treatment of dry eye disease; and NCX 1728, an NO-donating Phosphodiesterase-5 inhibitor, which is in preclinical evaluation. It offers VYZULTA, a latanoprostene bunod ophthalmic solution to treat patients with open-angle glaucoma or ocular hypertension; and ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis. The company was incorporated in 1996 and is headquartered in Valbonne, France.
ALCOX Stock 12 Month Forecast
Average Price Target
€1.50
▲(248.84% Upside)
Technical Analysis
GenSight Biologics SA
―
Advicenne SA
―
Valbiotis SA
―
Theranexus SA
―
NFL Biosciences SA
―